What does Preamble of HR 1518 do?

This bill aims to amend the Public Health Service Act. The stated purpose of the bill is to address preventing end-stage kidney disease. The bill was introduced in the House of Representatives on February 24, 2025.

What does SHORT TITLE. of HR 1518 do?

This bill is formally titled the New Era of Preventing End-Stage Kidney Disease Act.

What does CENTERS OF EXCELLENCE ON RARE KIDNEY DISEASE RESEARCH IN THE of HR 1518 do?

This section amends the Public Health Service Act to establish NIDDK Centers of Excellence on Rare Kidney Disease Research. The Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) may provide cooperative agreements and grants to public and private nonprofit entities to support these centers. The purposes of these centers include conducting research on rare kidney diseases, increasing public awareness, and developing resources for clinical research and training. Funds may be used for patient care costs related to research, clinical training, public information programs, and outreach to rural and underserved communities. Research funded through these grants must include study of genotype-phenotype relationships and cannot consider quality-adjusted life years or disability-adjusted life years in value and cost-effectiveness assessments. The initial period of support for a center is five years, with potential extensions of up to five years based on peer review recommendations. The section authorizes appropriations of $6,000,000 for each of fiscal years 2026 through 2030 to carry out these provisions.

What does UNDERSTANDING AND SLOWING THE PROGRESSION OF RARE KIDNEY of HR 1518 do?

This section directs the Secretary of Health and Human Services to conduct a study on testing, preventative care, precision medicine, and treatment related to rare kidney disease. The study will review the impact of routine urinalysis, the quality of kidney biopsies, and the utility of genetic and genomic tests, including APOL1 gene testing. The study will also examine social, behavioral, and biological factors contributing to rare kidney disease, treatment patterns, access to nephrologists, and patient trust. The Secretary must submit a report to Congress within 18 months of the Act's enactment, including recommendations. The Secretary is required to consult with various stakeholders during the study and report development. Coordination with the NIH Director, CMS Administrator, HRSA Administrator, and CMMI Director is mandated. The section authorizes $1,000,000 in appropriations for each fiscal year from 2026 through 2030 to carry out these activities.

What does PROVIDER EDUCATION. of HR 1518 do?

This section modifies the Public Health Service Act to expand training related to kidney disease. It amends Section 747(b)(3)(E) to include individuals with kidney disease, including rare kidney disease, in primary care training. It amends Section 736(b) to establish a new paragraph (7) to award fellowships for postgraduate training in nephrology. These fellowships aim to increase providers' knowledge of rare kidney disease prevention, diagnosis, and treatment, particularly for populations disproportionately impacted, including those with the APOL1 gene. The fellowships also seek to improve the quality of care for racial and ethnic minorities and increase the number of nephrologists trained to serve these populations.

What does DELAYING KIDNEY DISEASE IMPACT. of HR 1518 do?

This section amends Section 1881(f) of the Social Security Act. The Secretary is directed to conduct experiments to evaluate treatments for rare kidney disease, focusing on delaying or eliminating the need for dialysis and transplant. The Secretary must also conduct a comprehensive study to increase public awareness of rare kidney disease. A report detailing the experiments and study, along with recommendations for legislative changes, must be submitted to Congress within 24 months of the New Era of Preventing End-Stage Kidney Disease Act's enactment.

Back to bills

New Era of Preventing End-Stage Kidney Disease Act — HR. 1518

Last updated: 2/24/2025 · Introduced: 2/24/2025

Author: Gus Bilirakis (R-FL)

TL;DR (AI)

This bill establishes NIDDK Centers of Excellence on Rare Kidney Disease Research to conduct research, increase public awareness, and develop clinical resources, authorizing $6,000,000 annually from 2026-2030.
The Secretary of Health and Human Services will conduct a study on testing, preventative care, and treatment related to rare kidney disease, including an examination of social and biological factors, and will submit recommendations to Congress within 18 months, authorized at $1,000,000 annually from 2026-2030.
The bill expands training for healthcare providers on kidney disease, including rare kidney disease, by incorporating it into primary care training and establishing new nephrology fellowships focused on improving care for disproportionately impacted populations.

119th Congressin committeeOfficial page

Verified Votes

No verified votes yet.

Community Votes

No community votes yet. Be the first!

Voting as guest · Sign in for verified votes

Other Sections

Includes provisions on preamble, short title., and 4 more.

6 sections

Click "Show details" to explore individual sections. Use the community vote above or visit All Sections to vote per section.

Read official text

Want the full experience?

Create a free account to cast verified votes on each section, get a personalized summary, and track your voting history.

Create Free Account